Watanabe Todd sold $114K of ARQT

Watanabe Todd (See Remarks) sold 4,375 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $26.12 ($0.11M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Watanabe Todd
Published Aug 6, 2026, 1:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
medium confidence
Mentioned
$ARQT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

This provides a fresh, primary-source datapoint on insider selling activity, but it does not disclose new operational or financial information about ARQT.

02

Market read

A routine 10b5-1 open-market sale was reported, which may slightly influence sentiment but is unlikely to drive a fundamental repricing by itself.

03

What to watch

Traders may over-weight the headline sale size; the filing lacks context on total insider holdings, other concurrent sales, or whether the plan is regularly executed.

Relevance 3/10Novelty 3/10Timing: filed Aug 5, transaction dated Aug 3

Background

The article is a SEC Form 4 insider transaction disclosure for Arcutis Biotherapeutics, Inc.

Company-level read

Ticker impact

$ARQTNeutralMedium confidence
Context

Arcutis Biotherapeutics disclosed an officer/director open-market sale of 4,375 shares at $26.1168 on Aug 3 under a 10b5-1 plan.

Expected impact

Likely minimal, unless traders extrapolate unusual selling volume or interpret it as confidence erosion.

Evidence & confidence

Form 4 provides transaction details but does not include new company performance, guidance, or regulatory/clinical catalysts. The presence of a 10b5-1 plan typically reduces interpretive weight.

Market effects

No clear sector read-through; this is an issuer-specific insider transaction.

None indicated.

None indicated.

Counterpoint

Insider sales under 10b5-1 are often driven by diversification or liquidity needs and may not reflect bearish expectations.

Key entities

  • Arcutis Biotherapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Watanabe Todd

    Officer and director who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.